retatrutide weight loss results clinical trial Lilly's triple agonist achieves 16.8% in phase 3 Peptide Series #3 — Retatrutide

Gala's public-facing website describes access to GLP-1/GIP and microdosing GLP-1/GIP options

Recent Developments: Initiated Phase 3 trials for maritide (caftaglutide), targeting both GLP-1 and GIP receptors

The 12 mg format provides flexibility for large-scale experiments, receptor-binding assays, and extended signaling studies

Per HumeCare's Terms, membership automatically renews at the then-current rate unless canceled before your renewal date, and the company reserves the right to change pricing at any time, with the new rate taking effect at your next renewal rather than mid-term

The Frias et al

However, it's worth noting the brand relies on in-house, not third-party, testing